---
schema_version: "secwatch.filing_event.v1"
accession: "0000313616-26-000002"
form_type: "8-K"
ticker: "DHR"
cik: "0000313616"
company_name: "DANAHER CORP /DE/"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:58:56.189057+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Danaher estimates Q4 revenue up mid-single digits YoY; core revenue and FY EPS at high-end of guidance

## Summary
- Estimated Q4 2025 revenue up mid-single-digit percent YoY; non-GAAP core revenue growth toward high-end of low-single-digit guidance.
- Full-year 2025 adjusted diluted EPS expected toward high-end of $7.70–$7.80 guidance range.
- CEO cites continued strength in Bioprocessing and better-than-expected Life Sciences and Diagnostics revenue in Q4.
- Danaher will report full Q4 and FY2025 earnings on January 28, 2026.
- Presentation at J.P. Morgan Healthcare Conference on January 13; live webcast on Danaher's website.

## SEC filing metadata
- accession: 0000313616-26-000002
- form_type: 8-K
- ticker: DHR
- cik: 0000313616
- company_name: DANAHER CORP /DE/
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/313616/000031361626000002/0000313616-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/313616/000031361626000002/dhr-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000313616-26-000002
- JSON: https://secwatch.observer/filing/0000313616-26-000002.json
- Plain text: https://secwatch.observer/filing/0000313616-26-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.